UBIP
LIVE

Serial Number

97470141

Owner

UBI Pharma Inc.

Attorney

Joe McKinney Muncy

Filing Date

Jun 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

UBIP Trademark

Serial Number: 97470141 • Registration: 7739637

UBIP is a trademark filed by UBI Pharma Inc. on June 22, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

UBI Pharma Inc.

No.45, Guangfu N. RD., Hukou Township,
Hsinchu County 30351 , TW

Entity Type: 03

Trademark Details

Filing Date

June 22, 2022

Registration Date

March 25, 2025

Published for Opposition

July 18, 2023

Goods & Services

Antibiotics; Pre-filled syringes for medical purposes being syringes sold filled with pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Medicines for human purposes for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Contrast medium for medical use being contrast media for in vivo imaging; Ointments for pharmaceutical purposes being anti-biotic, anti-infective, and anti-inflammatory ointments; Poultices for pharmaceutical purposes being anti-biotic, anti-infective, and anti-inflammatory poultices; Western medicine, namely, pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Active pharmaceutical ingredients (APIs) for Western Medicine being pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Vitamin preparations; antiviral drug; biological preparations for medical purposes being biological preparations for the treatment of cancers, infections, metabolic diseases, neurological disorders; Hormones for medical purposes; Medicated skin lotions for pharmaceutical purposes; Medicinal drinks; Vaccines; chemico-pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, neurological disorders; Albuminous preparations for medical purposes, namely, pharmaceutical preparations featuring albumin peptides, proteins and complexes thereof for the treatment of cancers, infections, metabolic diseases, and neurological disorders; biological reagent for medical purposes; test reagent for medical purposes; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes

Providing research and development in the field of biological and pharmaceutical scientific research and development; Biological research; Bacteriological research; Clinical lab test of medical reagent being providing reagent sample testing for others for scientific research purposes; Clinical trials, namely, scientific research in the nature of conducting clinical trials for others; Research and analysis of medical reagent being medical research; medical research; Research and development of new products for others; Technical project studies being conducting of feasibility studies in the field of new technologies; Technical writing; Industrial analysis and research service in the field of pharmaceutical sciences; Rental of laboratory instruments; Scientific laboratory services; Technological consultancy in the field of biological and pharmaceutical manufacturing processes; scientific research and technological research in the field of biological and pharmaceutical manufacturing processes; culturing of cells for others for scientific research purposes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 25, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 25, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 3, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 3, 2025 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 14, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 15, 2024 GNFN
FINAL REFUSAL E-MAILED
Nov 15, 2024 GNFR
SU - FINAL REFUSAL - WRITTEN
Nov 15, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 22, 2024 CRFA
ASSIGNED TO LIE
Oct 22, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 11, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 12, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 12, 2024 GNRT
SU - NON-FINAL ACTION - WRITTEN
Apr 12, 2024 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Mar 16, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 11, 2024 AITU
USE AMENDMENT FILED
Feb 20, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Feb 20, 2024 EISU
ASSIGNED TO EXAMINER
Oct 23, 2023 DOCK
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 12, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 18, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 28, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 8, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 8, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 8, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 8, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 8, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 11, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 11, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 11, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 4, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 12, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 11, 2022 NWOS
NEW APPLICATION ENTERED
Jun 25, 2022 NWAP